Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


20 Items
Title  Creator  Group name  Publishing year 
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial Assenat et al. EquipeMY 2021-12
Management of colorectal peritoneal metastases: Expert opinion Abboud et al. EquipeMY Aug 26, 2019
Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs) Ronellenfitsch et al. EquipeMY Aug 2017
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies Del Rio et al. EquipePM Mar 08 2017
Imaged-guided liver stereotactic body radiotherapy using VMAT and real-time adaptive tumor gating. Concerns about technique and preliminary clinical results Llacer-Moscardo et al. EquipePM Mar-Apr 2017
Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment Thierry et al. EquipeMY Sep 01, 2017
Antibody targeting of claudin-1 as a potential colorectal cancer therapy Cherradi et al. EquipeMY 06 28, 2017
MACVIA-LR (Fighting Chronic Diseases for Active and Healthy Ageing in Languedoc-Roussillon): A Success Story of the European Innovation Partnership on Active and Healthy Ageing Bousquet et al. EquipeMY 2016
Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients Mbatchi et al. EquipeCG Apr 26 2016
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial? Delbaldo et al. EquipeMY Jun 2015
FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial Hebbar et al. EquipeMY May 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial Assenat et al. EquipePM May 20 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial Assenat et al. EquipeAP May 20 2015
[Should cases of hepatocellular carcinoma be discussed by non-specialized multidisciplinary team meetings?] Barbare et al. EquipeMY Jun 2014
Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies Heinemann et al. EquipeMY Feb 2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial Samalin et al. EquipeMY Mar 4 2014
RIP140 increases APC expression and controls intestinal homeostasis and tumorigenesis Lapierre et al. EquipeVC May 2014
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study Guimbaud et al. EquipeMY Nov 1 2014
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Thierry et al. EquipeMY Apr 2014
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort Pernot et al. EquipeMY Apr 2014
20 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés